N-Acetyl Selank Amidate
N-Acetyl Selank Amidate is a modified Selank analog in the Neuromodulator class. The parent peptide Selank is a synthetic analog of the immunomodulatory peptide tuftsin, reported in Russian-language research to modulate GABAergic and serotonergic signalling and to influence expression of brain-derived neurotrophic factor.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- intranasal
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Vendor price snapshot
Price per mg is list price divided by vial size in milligrams when both are known from public vendor listings. Peptide Library does not sell peptides. Confirm live prices on the vendor site.
- Vendors listing this peptide
- 2
- Listed offers
- 3
- Price per mg range
- $1.77–$4.00/mg
Research summary
Chemically modified analog of Selank with N-terminal acetylation and C-terminal amidation, sold as a research chemical and commonly used intranasally. Not FDA-approved. Published research on this modified form specifically is very limited; most available data concerns Selank itself.
Peptide Library's N-Acetyl Selank Amidate profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- intranasal
- Reconstitution Guide
- —
Science
Mechanism of Action
The parent peptide Selank is a synthetic analog of the immunomodulatory peptide tuftsin, reported in Russian-language research to modulate GABAergic and serotonergic signalling and to influence expression of brain-derived neurotrophic factor. Acetylation and amidation of the termini are standard medicinal-chemistry modifications intended to slow exopeptidase degradation and increase stability; comparative pharmacokinetic data against unmodified Selank has not been published.
Studies
- Optimization of the treatment of anxiety disorders with selank (class-level)
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank (class-level)
- Functional Connectomic Approach to Studying Selank and Semax Effects (class-level evidence)
- FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection (class-level evidence)
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats (class-level evidence)
Regulatory & research status
N-Acetyl Selank Amidate is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
N-Acetyl Selank Amidate: frequently asked questions
What is N-Acetyl Selank Amidate?
Chemically modified analog of Selank with N-terminal acetylation and C-terminal amidation, sold as a research chemical and commonly used intranasally. Not FDA-approved. Published research on this modified form specifically is very limited; most available data concerns Selank itself.
How does N-Acetyl Selank Amidate work?
The parent peptide Selank is a synthetic analog of the immunomodulatory peptide tuftsin, reported in Russian-language research to modulate GABAergic and serotonergic signalling and to influence expression of brain-derived neurotrophic factor. Acetylation and amidation of the termini are standard medicinal-chemistry modifications intended to slow exopeptidase degradation and increase stability; comparative pharmacokinetic data against unmodified Selank has not been published.
Is N-Acetyl Selank Amidate FDA approved?
No. N-Acetyl Selank Amidate is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to N-Acetyl Selank Amidate?
Compounds most often compared with N-Acetyl Selank Amidate include Selank, Semax, Tuftsin and Noopept. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Parent-compound evidence — Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr, 2015External reference
- Parent-compound evidence — Efficacy and possible mechanisms of action of the peptide anxiolytic selank, 2008External reference
- Class-level evidence — Functional Connectomic Approach to Studying Selank and Semax Effects — Dokl Biol Sci, 2020External reference
- Class-level evidence — FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection — Sci Transl Med, 2025External reference
- Class-level evidence — Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats — Bull Exp Biol Med, 2022External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This N-Acetyl Selank Amidate profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track N-Acetyl Selank Amidate research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →